LUTS associated with ureteral stents. hematuria, dysuria, pain , urgency , frequency, incontinance
Conditions
Interventions
Intervention 1: In the intervention group, tadalafil tablet (Chemidarou company) 10 mg once daily is given for 4 weeks by oral route. Intervention 2: In the control group, a placebo tablet (same shape
Treatment - Drugs
Placebo
In the intervention group, tadalafil tablet (Chemidarou company) 10 mg once daily is given for 4 weeks by oral route.
In the control group, a placebo tablet (same shape, size and color of tadalafil which was made from starch by Pharmacy faculty of Tabriz University of Medical Sciences) is given for 4 weeks by oral ro
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
15 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Male patients (+15 years) that underwent unilateral ureteral stenting. Exclusion criteria: Patient's refusal of study; high blood pressure; history of heart disease; history of respiratory disease; history of stroke; hypotension (systolic blood pressure less than 90 mmHg); hepatic and renal failure; history of retinitis pigmentosa; severe headache; consumption of nitrate drugs and a positive urine culture
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary symptoms (urgency; frequency; nocturia; dysuria; hematuria; incomplete emptying) in patients with ureteral stents. Timepoint: 4 Weeks after intervention (only at the end of study). Method of measurement: Standard questionnaire (USSQ).;Abdominal pain, flank pain, inguinal and genital pain and pain severity and its association with physical activity, rest, voiding,… in patients with ureteral stent. Timepoint: 4 Weeks after intervention (only at the end of study). Method of measurement: Standard questionnaire (USSQ).;General health in patient with ureteral stent. Timepoint: 4 Weeks after intervention (only at the end of study). Method of measurement: Standard questionnaire (USSQ).;Sexual matters in patients with ureteral stent. Timepoint: 4 Weeks after intervention (only at the end of study). Method of measurement: Standard questionnaire (USSQ).;Work performance in patients with ureteral stent. Timepoint: 4 Weeks after intervention (only at the end of study). Method of measurement: Standard questionnaire (USSQ). | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiovascular side effects. Timepoint: 4 Weeks after intervention (only at the end of study). Method of measurement: Questionnaire.;Musculoskeletal side effects. Timepoint: 4 Weeks after intervention (only at the end of study). Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Abbas Jabbari
Urology Department, Tabriz University of Medical Sciences
Outcome results
None listed